Price$123.96+19.46 (+18.62%)
2026-04-092026-07-14
News · 26 weeks102+65%
2026-01-252026-07-19
Mix7590d
- Insider36(48%)
- SEC Filings22(29%)
- Other14(19%)
- Analyst2(3%)
- Leadership1(1%)
Latest news
25 items- FDAFDA Approval for JIDEYTRO issued to NUVALENT INCSubmission status for NUVALENT INC's drug JIDEYTRO (ORIG-1) with active ingredient ZIDESAMTINIB has changed to 'Approval' on 07/22/2026. Application Category: NDA, Application Number: 220185, Application Classification: Type 1 - New Molecular Entity
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Nuvalent Inc.SCHEDULE 13G/A - Nuvalent, Inc. (0001861560) (Subject)
- INSIDERDirector by Deputization Flynn James E returned $427,056 worth of Class A Common Stock - Restricted Stock Units to the company (3,444 units at $124.00) and returned $2,138,807,800 worth of shares to the company (17,248,450 units at $124.00) (SEC Form 4) to satisfy withholding tax4 - Nuvalent, Inc. (0001861560) (Issuer)
- INSIDERDirector Meyers Michael L. returned 3,444 units of Class A Common Stock - Restricted Stock Units to the company, closing all direct ownership in the company (SEC Form 4) to cover taxes4 - Nuvalent, Inc. (0001861560) (Issuer)
- INSIDERChief Financial Officer Balcom Alexandra returned 41,100 units of Class A Common Stock - Restricted Stock Units to the company, was granted 14,350 units of Class A Common Stock - Performance Stock Units and returned 14,350 units of Class A Common Stock - Performance Stock Units to the company, closing all direct ownership in the company (SEC Form 4) to satisfy withholding tax4 - Nuvalent, Inc. (0001861560) (Issuer)
- INSIDERDirector Srivastava Sapna returned 3,444 units of Class A Common Stock - Restricted Stock Units to the company, closing all direct ownership in the company (SEC Form 4) (tax withholding)4 - Nuvalent, Inc. (0001861560) (Issuer)
- INSIDERDirector Oliger Christy J. returned 6,091 units of Class A Common Stock - Restricted Stock Units to the company, closing all direct ownership in the company (SEC Form 4) (tax liability)4 - Nuvalent, Inc. (0001861560) (Issuer)
- INSIDERDirector Squarer Ron returned 6,281 units of Class A Common Stock - Restricted Stock Units to the company, closing all direct ownership in the company (SEC Form 4) (tax liability)4 - Nuvalent, Inc. (0001861560) (Issuer)
- INSIDERChief Medical Officer Turner Christopher Durant returned 41,100 units of Class A Common Stock - Restricted Stock Units to the company, was granted 14,350 units of Class A Common Stock - Performance Stock Units and returned 14,350 units of Class A Common Stock - Performance Stock Units to the company, closing all direct ownership in the company (SEC Form 4) to satisfy tax liability4 - Nuvalent, Inc. (0001861560) (Issuer)
- INSIDERChief Development Officer Noci Darlene returned 41,100 units of Class A Common Stock - Restricted Stock Units to the company, was granted 14,350 units of Class A Common Stock - Performance Stock Units and returned 14,350 units of Class A Common Stock - Performance Stock Units to the company, closing all direct ownership in the company (SEC Form 4) to cover taxes4 - Nuvalent, Inc. (0001861560) (Issuer)
- INSIDEROfficer Lane Benjamin returned 29,433 units of Class A Common Stock - Restricted Stock Units to the company, was granted 7,120 units of Class A Common Stock - Performance Stock Units and returned 7,120 units of Class A Common Stock - Performance Stock Units to the company, closing all direct ownership in the company (SEC Form 4) (tax withholding)4 - Nuvalent, Inc. (0001861560) (Issuer)
- INSIDERChief Scientific Officer Pelish Henry E. returned 14,350 units of Class A Common Stock - Performance Stock Units to the company, returned 41,100 units of Class A Common Stock - Restricted Stock Units to the company and was granted 14,350 units of Class A Common Stock - Performance Stock Units, closing all direct ownership in the company (SEC Form 4) (withholding tax)4 - Nuvalent, Inc. (0001861560) (Issuer)
- INSIDERPresident and CEO Porter James Richard was granted 40,025 units of Class A Common Stock - Performance Stock Units, returned 40,025 units of Class A Common Stock - Performance Stock Units to the company and returned 121,350 units of Class A Common Stock - Restricted Stock Units to the company, closing all direct ownership in the company (SEC Form 4) (withholding obligation)4 - Nuvalent, Inc. (0001861560) (Issuer)
- INSIDERChief Legal Officer Miller Deborah Ann was granted 14,350 units of Class A Common Stock - Performance Stock Units, returned 14,350 units of Class A Common Stock - Performance Stock Units to the company and returned 41,100 units of Class A Common Stock - Restricted Stock Units to the company, closing all direct ownership in the company (SEC Form 4) (withholding obligation)4 - Nuvalent, Inc. (0001861560) (Issuer)
- INSIDERDirector Protopapas Anna returned 3,444 units of Class A Common Stock - Restricted Stock Units to the company, closing all direct ownership in the company (SEC Form 4) (withholding obligation)4 - Nuvalent, Inc. (0001861560) (Issuer)
- INSIDERDirector Wheeler Cameron returned 3,444 units of Class A Common Stock - Restricted Stock Units to the company, closing all direct ownership in the company (SEC Form 4) to cover withholding tax4 - Nuvalent, Inc. (0001861560) (Issuer)
- INSIDERDirector Bogle Grant C. returned 5,577 units of Class A Common Stock - Restricted Stock Units to the company, closing all direct ownership in the company (SEC Form 4) (withholding obligation)4 - Nuvalent, Inc. (0001861560) (Issuer)
- SECSEC Form 25-NSE filed by Nuvalent Inc.25-NSE - Nuvalent, Inc. (0001861560) (Subject)
- SECSEC Form POSASR filed by Nuvalent Inc.POSASR - Nuvalent, Inc. (0001861560) (Filer)
- SECSEC Form S-8 POS filed by Nuvalent Inc.S-8 POS - Nuvalent, Inc. (0001861560) (Filer)
- SECSEC Form S-8 POS filed by Nuvalent Inc.S-8 POS - Nuvalent, Inc. (0001861560) (Filer)
- SECSEC Form S-8 POS filed by Nuvalent Inc.S-8 POS - Nuvalent, Inc. (0001861560) (Filer)
- SECSEC Form S-8 POS filed by Nuvalent Inc.S-8 POS - Nuvalent, Inc. (0001861560) (Filer)
- SECSEC Form S-8 POS filed by Nuvalent Inc.S-8 POS - Nuvalent, Inc. (0001861560) (Filer)
- SECSEC Form S-8 POS filed by Nuvalent Inc.S-8 POS - Nuvalent, Inc. (0001861560) (Filer)
NUVL FAQ
7 questionsWhat does Nuvalent Inc. do?
Nuvalent, Inc., a preclinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor, designed to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors; and NVL-655, a brain-penetrant ALK-selective inhibitor, designed to inhibit ALK fusions that express the normal ALK kinase domain without any drug-resistant mutations and...Where does NUVL stock trade?
Nuvalent Inc. (NUVL) is listed on NASDAQ.What sector and industry is NUVL in?
Nuvalent Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Nuvalent Inc. go public?
Nuvalent Inc. (NUVL) completed its IPO in 2021.What are analysts saying about NUVL?
Nuvalent Inc. has had 8 recent analyst actions on file. The most recent action was from Bernstein: Mkt Perform on 2026-06-24.What companies are similar to NUVL?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare NUVL side-by-side with any of them on Quantisnow.How can I track NUVL on Quantisnow?
Quantisnow aggregates Nuvalent Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NUVL to receive live email and push alerts on every new disclosure.